This executive summary, excerpted from AVAC Report 2014/15, puts the current discussion about global targets for ending AIDS in context. What makes a good target? What targets have worked in the past—and why? What is the state of HIV prevention targets and plans today?
AVAC Report 2014/15: Prevention on the Line [Executive Summary]
Essential Actions for HIV Prevention Research Rollout 2014/15
This updated version of AVAC’s 3D graphic shows priorities across the research-to-rollout spectrum. The graphic appears in AVAC Report 2014/15: Prevention on the Line.
What do women want in multipurpose technologies?
Multipurpose Prevention Technologies (MPTs) are a fast-growing area in women’s sexual and reproductive health. On November 12, AVAC and CAMI Health co-hosted a webinar: MPT Acceptability in Uganda, Nigeria and South Africa.
Increasing National Impact and Uptake of Good Participatory Practice Guidelines for Biomedical HIV Prevention (GPP): Three Country Case Studies
GPP provides a systematic framework for stakeholder engagement. This infographic examines how GPP was applied to the national trial oversight process in three countries: Uganda, Thailand, and South Africa. The timline plots key GPP activities and milestones from 2011-2014. This poster was presented at the 2014 HIV Research for Prevention conference in South Africa.
Innovation in Stakeholder Engagement: Piloting a Monitoring and Evaluation Toolkit
The M&E toolkit was developed to better understand and assess the impact of engagement on clinical trials and communities. The tools and web-based analysis database were piloted in South Africa and Kenya. This poster, presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa, outlines the process and lessons learned.
Homophobic legislation and its Impact on Human Security
This report by the MSMGF explores the circumstances around the enactment of new anti-homosexual legislation in Nigeria and Uganda, examining five categories of insecurity faced by lesbian, gay, bisexual and transgender (LGBT) people in the context of these laws.
Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360) and Kristin Wall (Emory University), and Mary Lyn Gaffield from the WHO discussed the newest findings and guidance.
Creating a Prevention Agenda for Women: AVAC/CHANGE meeting for coordinated global advocacy
This report, released by CHANGE and cosponsored by AVAC, summarizes the key recommendations related to integration of HIV and family planning services, how to best move forward in the context of uncertainty about whether some hormonal contraceptives (HC) increase HIV risk, and how to advance “method mix”—a wider array of contraceptive choices for women everywhere.
Facing Questions about Hormonal Contraceptives and HIV: What’s next in getting answers?
In this webinar we learned about and discussed proposed research to directly evaluate how different family planning methods might impact HIV risk.
Trial designs are actively being discussed and funding is being sought for such research—but there are many questions where advocates’ voices are needed: What should a trial look like? How can method mix (the range of available family planning options) be expanded for all women? What can be done to better integrate HIV and family planning in the meantime?
View the full webinar here
Rectal Microbicides Video Facilitator’s Guide
This guide is meant to be used as a preparation tool for people leading community discussions, workshops, or recruitment sessions who will be showing the educational video. Background information on rectal microbicide research and the clinical trial process is included in the guide.